Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Purpose: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1) pathway inhibitor, in patients with advanced solid malignancies. Experimental Design: Patients with advanced solid malignancies received rigosertib twice daily continuously in 21-day cycles. Doses were escalated until intolerable grade ≥2 toxicities, at which point the previous dose level was expanded to define the MTD. All patients were assessed for safety, PK, and response. Urinary PK were performed at the MTD. Archival tumors were assessed for potential molecular biomarkers with multiplex mutation testing. A subset of squamous cell carcinomas (SCC) underwent exome sequencing. Results: Forty-eight patients received a median of 2 cycles of therapy at 5 dose levels. Rigosertib exposure increased with escalating doses. Dose-limiting toxicities were hematuria and dysuria. The most common grade ≥2 drug-related toxicities involved urothelial irritation. The MTD is 560 mg twice daily. Activity was seen in head and neck SCCs (1 complete response, 1 partial response) and stable disease for ≥12 weeks was observed in 8 additional patients. Tumors experiencing ≥partial response had PI3K pathway activation, inactivated p53, and unique variants in ROBO3 and FAT1, two genes interacting with the Wnt/β-catenin pathway. Conclusions: The recommended phase II dose of oral rigosertib is 560 mg twice daily given continuously. Urinary toxicity is the dose-limiting and most common toxicity. Alterations in PI3K, p53, and Wnt/β-catenin pathway signaling should be investigated as potential biomarkers of response in future trials. Clin Cancer Res; 20(6); 1656–65. ©2014 AACR.

[1]  A. Jimeno,et al.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins , 2013, Molecular oncology.

[2]  A. Jimeno,et al.  The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas , 2013, Molecular Cancer Therapeutics.

[3]  Simion I. Chiosea,et al.  Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. , 2013, Cancer discovery.

[4]  Juping Yuan,et al.  Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53 , 2013, Cell cycle.

[5]  S. Ambudkar,et al.  Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference , 2013, PloS one.

[6]  L. Liau,et al.  Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.

[7]  Takashi Ishikawa,et al.  High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival , 2013, Breast Cancer Research and Treatment.

[8]  Sheng-Cai Lin,et al.  PLK1 Interacts and Phosphorylates Axin That Is Essential for Proper Centrosome Formation , 2012, PloS one.

[9]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[10]  Razelle Kurzrock,et al.  A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[11]  R. Seethala,et al.  Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer , 2012, Clinical Cancer Research.

[12]  A. Wiestner,et al.  ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress , 2012, Clinical Cancer Research.

[13]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Bernhard Kuster,et al.  Quantitative Chemical Proteomics Reveals New Potential Drug Targets in Head and Neck Cancer* , 2011, Molecular & Cellular Proteomics.

[15]  K. Nakashiro,et al.  Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of β-catenin. , 2011, Oncology reports.

[16]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[17]  E. Reddy,et al.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. , 2011, Journal of medicinal chemistry.

[18]  S. Anand,et al.  A MEK-independent role for CRAF in mitosis and tumor progression , 2011, Nature Medicine.

[19]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[20]  A. Bosserhoff,et al.  Slit-2 facilitates interaction of P-cadherin with Robo-3 and inhibits cell migration in an oral squamous cell carcinoma cell line. , 2011, Carcinogenesis.

[21]  A. Jimeno,et al.  New phosphatidylinositol 3-kinase inhibitors for cancer , 2011, Expert opinion on investigational drugs.

[22]  Razelle Kurzrock,et al.  PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.

[23]  R. Hofheinz,et al.  An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[24]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[25]  J. Baselga,et al.  A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. , 2010 .

[26]  J. Kao,et al.  HPV-induced oropharyngeal cancer, immune response and response to therapy. , 2010, Cancer letters.

[27]  A. Jimeno,et al.  A Fine-Needle Aspirate–Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[28]  C. Tzao,et al.  SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis. , 2010, Cancer research.

[29]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[30]  E. Reddy,et al.  Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells , 2009, Oncogene.

[31]  A. Jimeno,et al.  Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[33]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[34]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[35]  Kiranmai Gumireddy,et al.  ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. , 2005, Cancer cell.

[36]  K. Strebhardt,et al.  Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. , 2004, Journal of the National Cancer Institute.

[37]  M. Tsao,et al.  Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. , 2004, Molecular cancer therapeutics.

[38]  Jianjun Cheng,et al.  Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles , 2004, Cancer biology & therapy.

[39]  J. Pines,et al.  Active cyclin B1–Cdk1 first appears on centrosomes in prophase , 2003, Nature Cell Biology.

[40]  Jürgen Bereiter-Hahn,et al.  Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. , 2002, Journal of the National Cancer Institute.

[41]  Ajay N. Jain,et al.  Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. , 2002, Cancer research.

[42]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[43]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[44]  H. Lane,et al.  On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. , 1997, Biochemical and biophysical research communications.

[45]  A. Awada,et al.  A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. , 2012, European journal of cancer.

[46]  西川 由希子.  Human FAT1 cadherin controls cell migration and invasion of oral squamous cell carcinoma through the localization of β-catenin , 2011 .

[47]  H. Sugerman,et al.  Association between Incident Cancer and Subsequent Stroke , 2015, Annals of neurology.

[48]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.